Cellectis S.A. (NASDAQ:CLLS) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET
Company Participants
Arthur Stril - Chief Business Officer
Andre Choulika - Chief Executive Officer
Carrie Brownstein - Chief Medical Officer
Bing Wang - Chief Financial Officer
Conference Call Participants
Gena Wang - Barclays
Yigal Nochomovitz - Citigroup
Kelly Shi - Jeffries
Jack Allen - Baird
Hartaj Singh - Oppenheimer
Raju Prasad - William Blair
Silvan Tuerkcan - JMP Securities
Operator
Greeting and welcome to the Cellectis First Quarter 2022 Corporate Update and Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder this conference is being recorded.
I would now like to turn the conference over to your host Mr. Arthur Stril, Chief Business Officer for Cellectis. Please go ahead, sir.
Arthur Stril
Good morning and welcome, everyone, to Cellectis’ first quarter 2022 corporate update and financial results conference call. Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chief Executive Officer; Dr. Carrie Brownstein, our Chief Medical Officer; and Dr. Bing Wang, our Chief Financial Officer.
Yesterday evening, Cellectis filed its interim reports and issued a press release reporting its financial results for the first quarter and three-months period ended March 31, 2022. The report and press release are available on our website at cellectis.com.
As reminder, we will make statements regarding Cellectis' financial outlook in addition to its manufacturing, regulatory, and product development plan. These forward-looking statements which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent Form 20-F filed with the SEC and the financial reports, including the management report for the year ending on December 31, 2021 and subsequently filings Cellectis makes with the Securities and Exchange Commission from time-to-time.
I would now like to turn the call over to Andre.
Andre Choulika
Thank you, Arthur. Good morning and thank you everyone for joining us today. Cellectis made progress with our pipeline this quarter. We took a notable step forward with the first pre-clinical data on UCART20x22, the allogeneic dual CAR T-cell product candidate being developed for patients with relapsed or refractory non-Hodgkin’s lymphoma or NHL.